The latent anti-PAF properties of fish PL usually occur either through affecting beneficially PAF-metabolism towards reduction of its levels of homeostatic ones and/or through inhibiting the binding of PAF on its receptor and thus inhibiting PAF-related inflammatory and thrombotic pathways and activities (Figure 2), and subsequently reducing the risk for inflammation related chronic disorders such as atherosclerosis, CVD, and cancer [26,27,28,29]. The gene discussed is PCLAF; the disease is atherosclerosis.